What are the recommendations for selecting and dosing non‑vitamin K oral anticoagulants (NOACs) for stroke prevention in patients with non‑valvular atrial fibrillation, considering renal function, age, weight, and bleeding risk?

NOACs for Stroke Prevention in Atrial Fibrillation

For patients with non-valvular atrial fibrillation requiring anticoagulation, NOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) should be prescribed over warfarin in most cases, with apixaban demonstrating the most favorable safety profile, particularly for gastrointestinal bleeding risk. 1, 2, 3

Agent Selection

The 2018 CHEST guidelines and 2014 Canadian guidelines provide clear direction: NOACs are preferred over warfarin for most patients with non-valvular AF 1, 2. Among the NOACs, while all four agents show similar efficacy for stroke prevention, apixaban consistently demonstrates lower gastrointestinal bleeding rates compared to dabigatran (HR 0.81), edoxaban (HR 0.77), and rivaroxaban (HR 0.72) 3. This advantage persists across age groups, including patients ≥80 years, and in those with chronic kidney disease 3.

Key Exclusions for NOACs:

• Mechanical prosthetic valves - use warfarin only 1, 4
• Rheumatic mitral stenosis - use warfarin only 1, 2
• **Severe renal impairment (CrCl <30 mL/min)** - use warfarin with good INR control (TTR >65-70%) 1, 5

Dosing by Renal Function

Renal function assessment is mandatory before initiating any NOAC and must be monitored at least annually, more frequently (2-3 times yearly) in moderate renal impairment 1, 5.

Mild CKD (CrCl 60-89 mL/min):

• Standard NOAC dosing applies 1
• No dose adjustment needed

Moderate CKD (CrCl 30-59 mL/min):

• Dabigatran 110 mg twice daily (150 mg not available in US; use 150 mg in other countries unless high bleeding risk) 5
• Rivaroxaban 15 mg once daily (reduced from 20 mg) 1, 5
• Apixaban 2.5 mg twice daily if 2 of 3 criteria present: age >80, weight <60 kg, creatinine >133 μmol/L; otherwise 5 mg twice daily 1, 6
• Edoxaban 30 mg once daily (reduced from 60 mg) 1

Severe CKD (CrCl 15-30 mL/min):

• Rivaroxaban 15 mg once daily - use with caution 1
• Apixaban 2.5 mg twice daily - use with caution 1
• Edoxaban 30 mg once daily - use with caution 1
• Dabigatran 75 mg twice daily (US only) - safety/efficacy not established 6

End-Stage Renal Disease (CrCl <15 mL/min or dialysis):

• Use warfarin with TTR >65-70% 1
• NOACs generally contraindicated
• Exception: In US only, apixaban 5 mg twice daily is FDA-approved for hemodialysis patients 1, 4

Age-Based Dosing Considerations

For patients ≥80 years on dabigatran, use 110 mg twice daily due to better balance between stroke and bleeding risk 5, 2. This recommendation is particularly important as elderly patients were more likely to receive apixaban in real-world practice 7.

Weight-Based Adjustments

Apixaban requires dose reduction to 2.5 mg twice daily when ≥2 of the following are present 6:

• Age ≥80 years
• Weight ≤60 kg
• Serum creatinine ≥1.5 mg/dL

Bleeding Risk Assessment

Calculate HAS-BLED score before initiating anticoagulation 5. A score ≥3 indicates high bleeding risk and warrants:

• More frequent monitoring
• Addressing modifiable risk factors (uncontrolled hypertension, labile INRs, concomitant NSAIDs/aspirin, alcohol excess)
• For high bleeding risk, prefer dabigatran 110 mg twice daily or rivaroxaban 15 mg once daily 5

Critical pitfall: High bleeding risk should prompt risk factor modification and careful monitoring, not avoidance of anticoagulation 5. The bleeding risk with dual antiplatelet therapy approaches that of oral anticoagulation, particularly in elderly patients 5.

Drug Interactions

Dabigatran 110 mg twice daily is recommended with concomitant P-glycoprotein inhibitors (e.g., verapamil) 5. Edoxaban has an unusual contraindication: do not use if CrCl >95 mL/min due to reduced drug exposure 4.

Common Dosing Errors

Real-world data reveal concerning patterns: 43% of patients with renal indications for dose reduction were potentially overdosed, increasing major bleeding risk (HR 2.19) 8. Conversely, 13.3% without renal indications were underdosed, increasing stroke risk (HR 4.87 for apixaban) 8. These errors occurred across all NOACs but were highest with rivaroxaban 9, 8.

To avoid dosing errors:

1. Calculate CrCl using Cockcroft-Gault equation (required for all NOAC dosing) 4
2. Document all dose-adjustment criteria (age, weight, renal function, drug interactions)
3. Reassess renal function at appropriate intervals based on baseline function 1, 5
4. Avoid empiric dose reduction in patients without specific criteria 10, 8

Concomitant Antiplatelet Therapy

The safety and efficacy of combining NOACs with antiplatelet agents is not established 6. In patients with chronic kidney disease requiring anticoagulation, concomitant antiplatelet therapy substantially elevates bleeding risk and should be used very judiciously 1.

Monitoring Requirements

Unlike warfarin, NOACs do not require routine coagulation monitoring 11. However:

• Assess renal function annually in stable patients 1, 5
• Assess renal function 2-3 times yearly in moderate CKD 1, 5
• Monitor hepatic function occasionally for factor Xa inhibitors 4
• NOACs contraindicated in severe hepatic dysfunction 4